Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) is a late-stage life sciences company focused on anti-inflammatory and anti-fibrotic therapies for heart disease. Lead drug CardiolRx is in the pivotal Phase III MAVERIC trial for recurrent pericarditis, with over 50% patient enrollment achieved across 15+ US cardiovascular centers. The Phase II ARCHER trial demonstrated significant improvement in heart structure for acute myocarditis patients, with results published in ESC Heart Failure. Pipeline includes CRD-38 for additional cardiac indications. Headquartered in Oakville, Ontario. Led by CEO David Elsley.
Phase III MAVERIC trial for recurrent pericarditis over 50% enrolled with full enrollment expected Q2 2026. ARCHER Phase II showed structural heart improvement published in peer-reviewed journal. $14.85M financing closed January 2026 extends cash runway to Q3 2027. Addressing large underserved cardiovascular markets with two clinical-stage programs.